A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib

Metastatic soft tissue sarcomas (STSs) management remains an unmet medical need. We assessed the activity and safety of regorafenib in patients with metastatic non-adipocytic STS who were previously treated with both chemotherapy and pazopanib.

Source: European Journal of Cancer - January 12, 2020 Category: Cancer & Oncology Authors: Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, Antoine Italiano, Sebastien Salas, Corinne Delcambre, Emmanuelle Bompas, Fran çois Bertucci, Esma Saada-Bouzid, Loïc Chaigneau, Christine Chevreau, Thomas Brodowicz, Emili Tags: Original Research Source Type: research